A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
about
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsPCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabClinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reductionThe genetics and screening of familial hypercholesterolaemiaLipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature reviewPCSK9 and triglyceride-rich lipoprotein metabolismProfile of evolocumab and its potential in the treatment of hyperlipidemiaGlycaemic Effects of Non-statin Lipid-Lowering TherapiesDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersPCSK9 inhibitors in the prevention of cardiovascular diseasePCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraRetargeting the management of hypercholesterolemia - focus on evolocumabEvolocumabPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futureNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaPCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to dateLDL-Cholesterol: Standards of Treatment 2016: A German Perspective.Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.PCSK9 and Atherosclerosis - Lipids and Beyond.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBFamilial hypercholesterolemia: developments in diagnosis and treatmentThe proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Nontraditional serum lipid variables and recurrent stroke risk.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.PCSK9 antibodies for the treatment of hypercholesterolemiaFamilial hypercholesterolemiaIdentifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach.Coronary heart disease and genetic variants with low phospholipase A2 activityAtherosclerosis: cell biology and lipoproteinsPCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trialEfficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
P2860
Q26741078-A306F99E-FBD9-4A05-86E6-84E5C671499BQ26747776-7C1BC385-D53C-4F98-BDC5-96F6A1D4D237Q26752950-1F4A8B87-982F-40DB-AE1B-C2D9F41177F6Q26753081-1ADB4E57-1FDB-4090-BABF-A8B6EA599C84Q26771862-4751A94F-4D84-438C-8C73-77148E3B5572Q26796287-1D60B8F3-5AA1-4FBA-889B-D11D50D0E140Q27004235-4D227D79-D7A9-4272-BBAC-308E9E4257A4Q28070152-7ACCD437-4DFB-4A9E-9513-5168C82420F6Q28070296-02DD5780-6965-4D22-B9BC-3616957FB11CQ28071452-6362FA48-FED1-4648-9987-8DC477C84CDBQ28073656-472EF6DD-8888-49AC-BD7F-C1D3FF9B83B5Q28077289-23363968-E761-4817-9C4F-3D06D67158D5Q28078902-D2E34D61-37E5-4318-902B-23DA4792D0C5Q28083595-2248B38C-8335-4A51-A895-FBC8567399FDQ28084156-B7605BC4-D116-418C-8A35-3B2D740E0AAAQ28275648-E0D5B6FF-5696-4E65-899B-CDF629BDC923Q30234612-C52CB9A4-3C15-4FC6-ABDA-1A4701D77FF0Q30244599-AED75A2B-668B-4FDB-A8C7-7F848DFD182DQ30248925-D01B5925-B12E-4156-9A3B-0E8791831C2FQ30833167-3B15D4CA-9108-4F9C-8CB1-212AFDDD5D9AQ33670893-ACFD6D4B-E150-4DA9-9F91-73CC1C2AAF2CQ33675963-4517E86A-8E6A-4637-9D3A-81DFC41E6E5AQ33904455-7817B8CB-6FC6-43A6-BB74-D65549E482DEQ33908782-63493830-74C7-433F-8D19-FB976B1873DCQ34106665-874C2087-859A-4281-A0AE-D886CBF1D6FCQ34355679-8E24BBBE-A328-4885-AADB-57202EC3841DQ34423344-15B4BE6C-3215-4F5C-98D4-2663C68D7245Q34430377-DCA4C91C-A13E-4546-8284-FD529AC7B74CQ34433146-1A4EA733-C04B-4F81-B102-C3F54B4D3D42Q34458693-BADFE24B-1E4D-416F-AA09-481EE90A3A8DQ34536594-2A4A58F9-DC22-440D-B0E5-07C11F09319CQ34774969-513F06AF-5982-4CA5-B7FE-C7EEA05E7A06Q34971772-EECD0CD1-2C5F-43EB-B694-86F4607FE335Q35079924-41AF9D29-68EA-478C-A25A-590904341EFAQ35116234-4E905510-40CB-4E71-84E3-05674DA320C4Q35241610-0AB9FC7E-BEFE-4EC8-A95D-D933C894F951Q35262593-49B501C1-A533-460D-B8E1-1517EA54FED3Q35603530-77A22CCC-A6BA-411B-A35C-5F35EB73EA9DQ35664577-18B4F4C6-7737-4DC1-9A80-E1DB3FF25640Q35671077-79C2D702-3CA5-4CDB-B78E-98E085593BBB
P2860
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
@en
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
@nl
type
label
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
@en
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
@nl
prefLabel
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
@en
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
@nl
P2093
P356
P1476
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
@en
P2093
Christie M Ballantyne
DESCARTES Investigators
Dirk J Blom
Evan A Stein
Kate Tsirtsonis
Lesley Burgess
Maria Laura Monsalvo
Michael Bolognese
P304
P356
10.1056/NEJMOA1316222
P407
P50
P577
2014-03-29T00:00:00Z